Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

Publisher： Karger

E-ISSN： 1421-9662|134|4|233-242

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.4, 2015-0, pp. : 233-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload

By  

Acta Haematologica, Vol. 138, Iss. 2, 2017-09 ,pp. : 119-128

Karger

Access to resources Recommend Favorite

Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia

By  

Acta Haematologica, Vol. 129, Iss. 2, 2012-11 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload

By  

TRANSFUSION, Vol. 55, Iss. 7, 2015-07 ,pp. : 1613-1620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

By  

Acta Haematologica, Vol. 123, Iss. 4, 2010-04 ,pp. : 220-225

Karger

Access to resources Recommend Favorite